Literature DB >> 12538427

Divergent nitric oxide bioavailability in men and women with sickle cell disease.

Mark T Gladwin1, Alan N Schechter, Frederick P Ognibene, Wynona A Coles, Christopher D Reiter, William H Schenke, Gyorgy Csako, Myron A Waclawiw, Julio A Panza, Richard O Cannon.   

Abstract

BACKGROUND: Although reduced endothelial nitric oxide (NO) bioavailability has been demonstrated in arteriosclerotic vascular disease, the integrity of this system in sickle cell disease remains uncertain. METHODS AND
RESULTS: We measured forearm blood flow in 21 patients with sickle cell disease (hemoglobin SS genotype) and 18 black control subjects before and after intra-arterial infusions of acetylcholine, nitroprusside, and the NO synthase inhibitor NG-monomethyl-L-arginine (L-NMMA). Endothelium-dependent vasodilation, measured by the percent increase in flow induced by acetylcholine infusion, was significantly greater than in controls (252+/-37% for patients versus 134+/-24% for controls; P<0.0001). However, there was a large sex difference in blood flow responses between female and male patients (340+/-46% versus 173+/-41%; P=0.035). Similarly, basal NO bioactivity, as measured by the percent decrease in flow induced by L-NMMA, was depressed in male compared with female patients (-17+/-5% versus -34+/-4%; P=0.01), as was the response to nitroprusside (86+/-21% versus 171+/-22%; P=0.008). L-NMMA reduced the blood flow response to acetylcholine in women, but not in men. Sex differences in vascular cell adhesion molecule-1 were appreciated, with significant correlations between levels of soluble vascular cell adhesion molecule-1 and blood flow responses to L-NMMA and nitroprusside (r=0.53, P=0.004 and r=-0.66, P<0.001, respectively).
CONCLUSIONS: NO bioavailability and NO responsiveness are greater in women than in men with sickle cell disease and determines adhesion molecule expression. Endothelium-dependent blood flows are largely non-NO mediated in male patients. These results provide a possible mechanism for reported sex differences in sickle cell disease morbidity and mortality and provide a basis for novel pharmacological interventions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12538427     DOI: 10.1161/01.cir.0000044943.12533.a8

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  87 in total

Review 1.  Vasculopathy and pulmonary hypertension in sickle cell disease.

Authors:  Karin P Potoka; Mark T Gladwin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-11-14       Impact factor: 5.464

2.  Atorvastatin reduces serum cholesterol and triglycerides with limited improvement in vascular function in adults with sickle cell anemia.

Authors:  Candice Bereal-Williams; Roberto F Machado; Vicki McGowan; Amy Chi; Christian J Hunter; Gregory J Kato; Lori Hunter; Carole K Dalby; Kristine Partovi Hauser; Anitaben Tailor; Richard O Cannon
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

3.  Changes in Conjunctival Hemodynamics Predict Albuminuria in Sickle Cell Nephropathy.

Authors:  Ali Kord Valeshabad; Justin Wanek; Santosh L Saraf; Bruce I Gaynes; Victor R Gordeuk; Robert E Molokie; Mahnaz Shahidi
Journal:  Am J Nephrol       Date:  2015-08-05       Impact factor: 3.754

4.  Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality.

Authors:  Gregory J Kato; Sabrina Martyr; William C Blackwelder; James S Nichols; Wynona A Coles; Lori A Hunter; Marie-Luise Brennan; Stanley L Hazen; Mark T Gladwin
Journal:  Br J Haematol       Date:  2005-09       Impact factor: 6.998

5.  Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice.

Authors:  Dhananjay K Kaul; Xiao-du Liu; Hee-Yoon Chang; Ronald L Nagel; Mary E Fabry
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

6.  Endothelial function in patients with sickle cell anemia during and after sickle cell crises.

Authors:  Arnon Blum; Shay Yeganeh; Aviva Peleg; Fina Vigder; Konstantin Kryuger; Ahmed Khatib; Khalid Khazim; Harold Dauerman
Journal:  J Thromb Thrombolysis       Date:  2005-04       Impact factor: 2.300

7.  The effect of fetal hemoglobin on the survival characteristics of sickle cells.

Authors:  Robert S Franco; Zahida Yasin; Mary B Palascak; Peter Ciraolo; Clinton H Joiner; Donald L Rucknagel
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

8.  Oxidative stress and inflammation in iron-overloaded patients with beta-thalassaemia or sickle cell disease.

Authors:  Patrick B Walter; Ellen B Fung; David W Killilea; Qing Jiang; Mark Hudes; Jacqueline Madden; John Porter; Patricia Evans; Elliott Vichinsky; Paul Harmatz
Journal:  Br J Haematol       Date:  2006-10       Impact factor: 6.998

9.  Cell-Free Plasma Hemoglobin and Male Gender Are Risk Factors for Acute Kidney Injury in Low Risk Children Undergoing Cardiopulmonary Bypass.

Authors:  Nahmah Kim-Campbell; Catherine Gretchen; Clifton Callaway; Kathryn Felmet; Patrick M Kochanek; Timothy Maul; Peter Wearden; Mahesh Sharma; Melita Viegas; Ricardo Munoz; Mark T Gladwin; Hülya Bayir
Journal:  Crit Care Med       Date:  2017-11       Impact factor: 7.598

10.  Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress.

Authors:  Dhananjay K Kaul; Xiaoqin Zhang; Trisha Dasgupta; Mary E Fabry
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-02       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.